Get started
Author

Kamonlapat Supimon

Observed names: K. Supimon, Supimon, Kamonlapat
ORCID: 0000-0002-6354-9055
Observed ORCID: 0000-0002-6354-9055
OpenAlex ID: A5014063904
Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma
2021 · Kamonlapat Supimon, Thanich Sangsuwannukul, et al. · Scientific Reports · 72
PDF
Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells
2020 · Thanich Sangsuwannukul, Kamonlapat Supimon, et al. · International Immunopharmacology · 49
Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells
2022 · Kamonlapat Supimon, Thanich Sangsuwannukul, et al. · Cytotherapy · 20
Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
2022 · Thanich Sangsuwannukul, Kamonlapat Supimon, et al. · PLoS ONE · 10
PDF
Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach
2025 · Punchita Rujirachaivej, Teerapong Siriboonpiputtana, et al. · Journal of Translational Medicine · 6
PDF
Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1
2023 · Piriya Luangwattananun, Thanich Sangsuwannukul, et al. · International Immunopharmacology · 6
Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells
2024 · Kamonlapat Supimon, Thanich Sangsuwannukul, et al. · International Immunopharmacology · 3
T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy
2025 · Thanich Sangsuwannukul, Benjamin Kendall, et al. · Molecular Therapy · 2
Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma
2025 · Krissada Natungnuy, Piriya Luangwattananun, et al. · Cytotherapy · 1
Abstract 1779: Fourth-generation chimeric antigen receptor T cells targeting mucin 1 against breast cancer
2023 · Kamonlapat Supimon, Thanich Sangsuwannukul, et al. · Cancer Research · 1
Abstract 4105: Improvement of CD133-specific chimeric antigen receptor T cells by secreting anti-PD-L1 single-chain variable fragment against cholangiocarcinoma
2023 · Thanich Sangsuwannukul, Kamonlapat Supimon, et al. · Cancer Research · 1
Fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced anti-tumor activity against breast cancer
2026 · Kamonlapat Supimon, Thanich Sangsuwannukul, et al. · Cancer Immunology Immunotherapy
Dual bispecific protein engagers targeting mesothelin and NECTIN2 deliver CD3/CD28 signals to activate cytotoxic T cells against colorectal cancer patient-derived organoids
2026 · Suyanee Thongchot, Kamonlapat Supimon, et al. · Scientific Reports
Dual bispecific protein engager–armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma
2026 · Thanida Chanpong, Nunghathai Sawasdee, et al. · Biomedicine & Pharmacotherapy
Raw qPCR gene expression datasets associated with fourth-generation CAR T-cell therapy targeting CD133 and integrin αvβ6 in cholangiocarcinoma xenograft models
2026 · Plengsuriyakarn, Tullayakorn, Tarasuk, Mayuri, et al. · Zenodo (CERN European Organization for Nuclear Research)
336 Dual bispecific protein engager-armed T cells targeting FRα and PD-L1 enhance cytotoxicity against breast cancer cells
2025 · Piriya Luangwattananun, Thanawitch Sangkheereeput, et al. · Regular and Young Investigator Award Abstracts
PDF
56P Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
2024 · J. Sujjitjoon, T. Sangsuwannukul, et al. · Immuno-Oncology Technology
PDF
Works count: 20
Citation count: 170
H-index: 6
I10-index: 4
Year
Topic
Type